Page 198 - rcv31n3.vp

Actualización en medicamentos antidiabéticos y riesgo cardiovascular Revista Uruguaya de Cardiología
María del Pilar Serra Sansone Volumen 31 | nº 3 | Diciembre 2016

94. Wilcox R, Bousser MG, Betteridge DJ, Schern- 105. Monami M, Ahrén B, Dicembrini I, Mannucci E.
thaner G, Pirags V, Kupfer S, et al; PROactive Dipeptidyl peptidase-4 inhibitors and cardiovascular
Investigators. Effects of pioglitazone in patients with risk: a meta-analysis of randomized clinical trials. Dia-
type 2 diabetes with or without previous stroke: results betes Obes Metab 2013; 15(2):112-20.
from PROactive (PROspective pioglitAzone Clinical
106. Tremblay AJ, Lamarche B, Deacon CF, Weisna-
Trial In macroVascular Events 04). Stroke 2007;
gel SJ, Couture P. Effect of sitagliptin therapy on
38(3):865-73.
postprandial lipoprotein levels in patients with type 2
95. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kup- diabetes. Diabetes Obes Metab 2011; 13(4):366-73.
fer S, Perez A, et al; PERISCOPE Investigators.
107. Matikainen N, Mänttäri S, Schweizer A, Ulves-
Comparison of pioglitazone vs glimepiride on progres-
tad A, Mills D, Dunning BE, et al. Vildagliptin the-
sion of coronary atherosclerosis in patients with type 2
rapy reduces postprandial intestinal triglyceride-rich
diabetes:thePERISCOPErandomizedcontrolledtrial.
lipoprotein particles in patients with type 2 diabetes.
JAMA 2008; 299(13):1561-73.
Diabetologia 2006; 49(9):2049-57.
96. Mazzone T, Meyer PM, Feinstein SB, Davidson 108. Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ra-
MH, Kondos GT, D’Agostino RB Sr, et al. Effect of gonesi PD,QuerciF,etal. Effects of sitagliptin or
pioglitazone compared with glimepiride on carotid inti- metformin added to pioglitazone monotherapy in
ma-media thickness in type 2 diabetes: a randomized poorly controlled type 2 diabetes mellitus patients. Me-
trial. JAMA 2006; 296(21):2572-81. tabolism 2010; 59(6):887-95.
97. Langenfeld MR, Forst T, Hohberg C, Kann P, 109. Matsubara J, Sugiyama S, Akiyama E, Iwashita
LübbenG,KonradT,etal. Pioglitazone decreases S, Kurokawa H, Ohba K, et al. Dipeptidyl peptida-
carotid intima-media thickness independently of glyce- se-4 inhibitor, sitagliptin, improves endothelial
miccontrolinpatientswithtype2diabetesmellitus:re- dysfunction in association with its anti-inflammatory
sults from a controlled randomized study. Circulation effects in patients with coronary artery disease and un-
2005; 111(19):2525-31. controlled diabetes. Circ J 2013; 77(5):1337- 44.

98. Tzoulaki I, Molokhia M, Curcin V, Little MP, Mi- 110. van Poppel PC, Netea MG, Smits P, Tack CJ. Vil-
llett CJ, Ng A, et al. Risk of cardiovascular disease dagliptin improves endothelium-dependent vasodilata-
and all cause mortality among patients with type 2 dia- tion in type 2 diabetes. Diabetes Care 2011;
betes prescribed oral anti diabetes drugs: retrospective 34(9):2072-7.
cohort study using UK general practice research data-
111. Matheeussen V, Jungraithmayr W, De Meester I.
base. BMJ 2009; 339:b4731.
Dipeptidyl peptidase 4 as a therapeutic target in ische-
99. Morgan CL, Poole CD, Evans M, Barnett AH, mia/reperfusion injury. Pharmacol Ther 2012;
Jenkins-Jones S, Currie CJ. What next after met- 136(3):267-82.
formin?: a retrospective evaluation of the outcome of 112. Williams-Herman D, Engel SS, Round E, John-
second-line, glucose-lowering therapies in people with sonJ,GolmGT, GuoH,etal. Safety and tolerability
type 2 diabetes. J Clin Endocrinol Metab 2012; of sitagliptin in clinical studies: a pooled analysis of
97(12):4605-12. data from 10,246 patients with type 2 diabetes. BMC
Endocr Disord 2010; 10:7.
100. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the
treatment of type 2 diabetes: a comparative review. 113. Engel SS, Golm GT, Shapiro D, Davies MJ, Kauf-
Diabetes Obes Metab 2011; 13(1):7-18. manKD, GoldsteinBJ. Cardiovascular safety of si-
tagliptin in patients with type 2 diabetes mellitus: a
101. Scheen AJ. DPP-4 inhibitors in the management of
pooled analysis. Cardiovasc Diabetol 2013; 12:3.
type 2 diabetes: a critical review of head-to-head trials.
Diabetes Metab 2012; 38(2):89-101. 114. Schweizer A, Dejager S, Foley JE, Couturier A,
Ligueros-Saylan M, Kothny W. Assessing the car-
102. Karagiannis T, Paschos P, Paletas K, Matthews
dio-cerebrovascular safety of vildagliptin: meta-analy-
DR, Tsapas A. Dipeptidyl peptidase-4 inhibitors for
sis of adjudicated events from a large Phase III type 2
treatment of type 2 diabetes mellitus in the clinical set-
diabetes population. Diabetes Obes Metab 2010;
ting: systematic review and meta-analysis. BMJ 2012;
12(6):485-94.
344:e1369.
115. Frederich R, Alexander JH, Fiedorek FT, Dono-
103. Jackson EK. Dipeptidyl peptidase IV inhibition alters vanM,BerglindN,HarrisS,etal. A systematic as-
the hemodynamic response to angiotensin-converting sessment of cardiovascular outcomes in the saxagliptin
enzyme inhibition in humans with the metabolic drug development program for type 2 diabetes. Post-
syndrome. Hypertension 2010; 56(4):581-3. grad Med 2010; 122(3):16-27.
104. Monami M, Lamanna C, Desideri CM, Mannucci 116. Cobble ME, Frederich R. Saxagliptin for the treat-
E. DPP-4 inhibitors and lipids: systematic review and mentoftype2diabetesmellitus:assessingcardiovascu-
meta-analysis. Adv Ther 2012; 29(1):14-25. lar data. Cardiovasc Diabetol 2012; 11:6.
542